Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarus Keeping Commercial Options Open For Oral Testosterone Jatenzo

Executive Summary

Jatenzo – the first oral testosterone cleared by US FDA – will compete against injectable and topical formulas in a field that has suffered safety worries in the past. Clarus has a jump on oral rival Lipocine.

You may also be interested in...



Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia

The latest drug development news and highlights from our US FDA Performance Tracker.

Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval

US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.

‘Low-T’ Drugs Need Randomized CV Safety Trials, FDA Panel Says

Advisory committees also vote to change indication of testosterone replacement therapies, saying new trials are needed if sponsors want to win the old claims back.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124986

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel